ABSTRACT
INTRODUCTION
Primary malignant brain tumors (gliomas) are one of the deadliest neoplasia, which carry poor prognosis for patients despite current aggressive multimodal therapies (1); (2) . Human gliomas are highly vascularized (3) and grow in a space-occupying manner and thereby impinge on eloquent (functional) brain structures causing profound neurological impairments.
This process is often exacerbated by the mass effects of tumor-associated brain swelling leading to pressure-induced brain damage due to the limited space within the rigid skull.
Brain edema crucially contributes to the clinical course and outcome of patients with gliomas (4) and has been confirmed in experimental settings with mice (5) . One critical cytotoxic mechanism for edema formation has recently been identified with the glutamate transporter xCT at center stage (6) . xCT (also known as SLC7A11 as the regulatory part of system x c − ) is the catalytic domain of a heteromeric transporter including a heavy chain subunit (CD98/SLC3A2/4F2hc). Expression of both subunits is increased in patients suffering from malignant gliomas (7) (8) . xCT imports cystine in exchange of the amino acid and neurotransmitter glutamate, which released into the extracellular milieu at neurotoxic concentrations (9) (10) . Preclinical studies demonstrated that xCT inhibition in brain tumors reduces neuronal degeneration, glutamate-induced epilepsy and alleviates perifocal edema formation (6) (11) . In addition, xCT expression correlates with malignancy in humans (7, 12) .
However, whether the glutamate released by the antiporter xCT additionally executes vasogenic functions which lead to brain edema is currently not defined (13) . Also, whether glutamate receptor activation occurs in endothelial cells in relation to angiogenesis has not been investigated. (14) .
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To evaluate the influence of xCT-induced and glutamate on brain tumor growth apart from edema, we investigated the vasculature found in gliomas and assessed xCT-dependent tumor angiogenesis. These analyses allowed us to unravel the role of excitatory amino acid glutamate in tumor vessels and angiogenesis. We found that endothelial cells utilize NMDAR for vasculature formation, indicating a novel biological aspect of glutamate signaling.
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RESULTS
Perturbed xCT expression impacts tumor angiogenesis
We first investigated whether alteration of the glutamate antiporter xCT would affect gliomainduced cell death in the tumor microenvironment. To gain detailed insights into this, we implanted GFP-expressing glioma cells (WT) into brain tissue harboring the complex microenvironment including all cellular constituents of the brain. Wild-type gliomas strongly proliferated in brain parenchyma, and this massive growth was accompanied by increased neuronal cell death (Suppl. Fig. 1 a, b) . Interestingly, tumor-induced cell death was alleviated in xCT knock down (xCT KD ) gliomas in comparison to wild-type tumors (81 ± 4 % vs. 100 ± 5 %) (Suppl. Fig. 1 a, b) . To validate this finding, we analyzed gliomas overexpressing the glutamate transporter xCT (xCT OE gliomas). These tumors showed increased levels of glutamate secretion into the extracellular environment compared to wildtype gliomas (69 ± 4 µM vs. 51 ± 3 µM Glu ex in conditioned media), whereas xCT silenced gliomas showed diminished glutamate secretion (30 ± 5 µM Glu ex ) (Suppl. Fig. 1 c) . In addition, xCT overexpressing gliomas induced elevated levels of neuronal cell death exceeding the impact of wild-type glioma levels (135 ± 8 % vs. 100 ± 5 %) (Suppl. Fig. 1 ).
Besides tumor-associated neurodegeneration, another relevant malignancy criterion in human gliomas is the extent of newly formed vessels, or tumor angiogenesis. Thus, we further analyzed the potency to induce angiogenesis in these tumors ex vivo. Wild-type rodent and human gliomas revealed augmented peritumoral vessel growth whereas xCT KD gliomas showed normalized vessels with decreased numbers (Fig. 1 a, b ; Suppl. Fig. 2 ).
Interestingly, xCT OE gliomas displayed increased radial vessels ( Fig. 1 a, b ; Suppl. Fig. 2 ).
These data indicate that the glutamate transporter xCT in tumor cells is able to trigger neoangiogenesis and shapes tumor vessels.
To gain additional insights into the mechanisms of xCT-induced angiogenesis, we investigated the effects of secreted factors derived from gliomas in established angiogenesis assays. For this, we applied conditioned media from wild-type, xCT KD and xCT OE gliomas to cultured aortic rings. Conditioned media derived from wild-type gliomas induced endothelial Fan et al., 6 sprouting in cultured aortic explants whereas conditioned media from xCT KD provoked solely minor effects ( Fig. 1 c, d ). In contrast, xCT OE conditioned media promoted endothelial sprouting ( Fig. 1 c, d ). Since xCT OE gliomas release high amounts of glutamate into the extracellular microenvironment, we speculated that this amino acid mediates the observed pro-angiogenic response. Therefore, we performed an organotypic brain vascular sponge assay and implanted glutamate loaded cubes onto brain sections and monitored the vascular response ( Fig. 1 e) . Glutamate-loaded cubes altered the vasculature dramatically and attracted many vessels in comparison to control cubes loaded solely with the solvent (Fig. 1 e, f).
We next cultured matrigel-embedded aortic explants in DMEM medium without supplements.
After initial endothelial cell sprouting, we started to treat the tissue samples with glutamate and quantified the angiogenic response ( Fig. 2 a, b) . Treatment of aortic explant cultures with 100 µM glutamate increased endothelial sprouting significantly compared to controls ( Fig. 2 a, b) . To test whether this effect was caused by glutamate receptor-mediated signaling, we utilized various ionotropic glutamate receptor antagonists specifically directed against NMDA and AMPA subtypes. NMDARs were blocked with the non-competitive antagonist MK801 and we monitored the vascular response. The glutamate-induced endothelial sprouting effect was abolished when aortic rings were treated with the specific NMDAR antagonist MK801 (MK, 100 µM), whereas MK801 alone did not affect endothelial cell viability nor endothelial sprouting ( Fig. 2 a, b) . Next, we used the non-competitive AMPAspecific antagonist GYKI52466 (GYKI) applied at 50 µM to aortic explant cultures. In contrast, blocking glutamatergic AMPA receptors with GYKI did not abolish the outgrowthpromoting effects of glutamate. Endothelial sprouting was still significantly increased compared to controls (Fig. 2 b) . These experiments indicate that glutamate induces endothelial sprouts probably specifically via NMDAR subtype signaling.
To redefine our observation for gliomas, rat brain endothelial cells were tested for their capacity to form vascular tubes under glutamate application. These experiments revealed that brain endothelial cells display increased total length of vascular tubes when treated with Fig. 3 ). This glutamate-induced tube formation activity could be blocked with the NMDAR antagonist MK801 but remained intact with the AMPAR antagonists GYKI (Suppl. Fig. 3 a, b) .
Next, we studied the role of glutamate ex vivo and monitored the retinal vasculature.
Glutamate application significantly increased endothelial sprouts. This effect was reversed by simultaneous application of the NMDAR antagonist MK801, whereas inhibition of AMPA receptor signaling did not alter tube formation (Fig. 2 c, d ). Next, we investigated the impact of glutamate signaling on endothelial cell migration. For this, we measured the migration distance after glutamate treatment and NMDA and AMPA receptor inhibition (Fig. 2 e) .
Additional glutamate application increased endothelial cell migration slightly in the endothelial growth medium with a basal glutamate level of 100 µM ( Fig. 2 e, f) . Moreover, NMDAR specific antagonists MK801, AP5, and NK reduced endothelial migration significantly, whereas AMPAR specific antagonists such as GYKI did not affect endothelial migration ( Fig. 
e, f).
To further analyze whether glutamate acts as an endothelial growth factor, we determined endothelial proliferation. Dose-response analysis revealed that glutamate at various concentrations ranging from 10 µM up to 200 µM does not significantly foster endothelial cell proliferation ( Fig. 2 g ). We corroborated these findings by testing whether interference with the NMDAR signaling can normalize xCT-induced tumor angiogenesis, i.e. shifting vascular parameters to control levels. For this, we compared brain tumor vessels under control conditions and MK801 application in xCT overexpressing gliomas. Noteworthy, blocking NMDAR in the organotypic tumor microenvironment (VOGiM) led to reduced numbers of tumor vessels compared to untreated controls ( Fig. 2 h, i) . Thus, these data indicate that glutamate acts directly on endothelial cells in an NMDAR-dependent manner.
xCT-induced vessels are functionally perfused in vivo
We continued analyzing the vascular architecture in WT, xCT KD and xCT OE glioma implanted animals in vivo (Fig. 3) . In contrast to WT gliomas, xCT KD gliomas showed reduced vessel Fan et al.,
8 density (Fig. 3 a) . Conversely, xCT OE gliomas displayed an increased number of vessels (Fig. 3 a) . Moreover, xCT OE gliomas showed reduced neuronal cell survival (Fig. 3 b) . Thus, these data corroborate the findings from the ex vivo VOGiM experiments indicating that xCT is an effective target for inhibiting tumor angiogenesis.
Next, we investigated the functionality of newly formed vessels to estimate the involvement of xCT in vasogenic edema. For this, we performed cerebral intravital microscopy on mice bearing orthotopically implanted brain tumor spheroids. Interestingly, brain tumors from xCT OE glioma cells showed increased values of functional vessel length compared to wild type gliomas (Fig. 3 c-f , significant values marked with hash). Hence, xCT OE gliomas displayed high microvascular permeability at day 7 and 10 compared to wild-type gliomas and approached similar permeability values as wild-type gliomas at later time points (Fig. 3 c-f). Conversely, xCT KD gliomas showed reduced functional vessel density whereas the microvascular permeability and velocity were comparable to values of wild-type gliomas ( 
NMDAR mediated glutamate signaling in endothelial cells
To unveil the underlying mechanisms of glutamate mediated-effects on the tumor vasculature, we tested the endothelium for NMDAR expression. First, we analyzed the expression of the NMDAR subtypes in whole aortic tissue to confirm the responsiveness to glutamate. Quantitative RT-PCR analysis revealed that NMDAR subunits are present in the aortic samples (Fig. 4 a, b) . Hence, we investigated the glutamate receptor expression in isolated endothelial cells. Aortic endothelial cells (aEC) as well as brain endothelial cells (bEC) express NMDAR subunits with NR1 and NR2a in higher amounts compared to gliomas (Fig. 4 c, d ). Consistent with previous reports, immune-cytochemical investigations revealed that CD31-positive endothelial cells derived from aorta and brain both express the NMDAR pan-subunit NR1 (15) (16) (Fig. 4 e) . Moreover, we demonstrate that the NMDAR subunit NR1 is expressed in the vasculature of retinas and brain sections (Fig. 4 f) . (Fig. 4 g, h) . In addition, we tested whether NMDAR-dependent MAPK activation is inducible in endothelial cells. Therefore, we applied various concentrations of glutamate on endothelial cells and determined the NMDA downstream effector MAPK. We found that glutamate induced elevated phosphorylation of MAPK compared to controls, indicating a functional NMDA receptor activation (Fig. 4 i-j) . To further test whether glutamate acts in a receptor-mediated manner on endothelial cells via NMDA activation, we pretreated endothelial cells with MK801 before glutamate application.
These experiments showed that Akt activation was reduced following NMDAR inhibition, confirming that glutamate mediates receptor-dependent signals in endothelial cells (Fig. 4 k) .
We further investigated NMDAR-dependent responses in endothelial cells. Glutamate application on endothelial cells evoked a significant Ca 2+ release (Fig. 4 l) . Importantly, this glutamate-dependent Ca 2+ response could be abolished by application of the NMDAR inhibitor MK801 (Fig. 4 l, m) . Altogether, these data indicate that endothelial cells transduce glutamate signaling through NMDAR downstream kinases and Ca 2+ responses.
Inducible NMDAR1 knockout mice reveal compromised endothelial sprouts and vessel density
To study the role of glutamate-mediated angiogenesis in vivo, and to circumvent the embryonic lethality of a global knockout of the NMDA receptor subunit NR1 (GRIN1) (19), we generated inducible endothelial-cell specific genetic loss-of-function mutants (GRIN i∆EC ).
LoxP-flanked NMDAR1 allelic mice (GRIN fl/fl ) were crossed with transgenic mice expressing the tamoxifen-inducible recombinase CreERT2 under the control of the endothelium-specific
Cdh5 promoter. First, we tested the angiogenic potential of endothelia in aortic explant cultures. Following tamoxifen administration, controls displayed increased sprout formation and vascular density in the presence of glutamate (Fig. 5 a, b) . In contrast, GRIN i∆EC mutants showed significantly reduced endothelial sprouting and endothelial density (Fig. 5 a, b) .
Moreover, induced endothelial-cell-specific deletion of NMDAR1 between postnatal day 1 (P1) and P4 revealed that endothelial sprouting and vascular meshes were strongly reduced in GRIN i∆EC retinas after glutamate treatment compared to control littermates (Fig. 5 c, d ).
Moreover, endothelial-cell-specific deletion of NMDAR1 significantly reduced the number of endothelial filopodia in vivo (Fig. 5 e, f) .
Hence, we investigated whether NMDAR expression in brain endothelial cells has an impact on tumor-induced angiogenesis. Therefore, we implanted syngeneic gliomas orthotopically into brains of wildtype controls and GRIN i∆EC mice and monitored tumor vessels (Fig. 5 g ).
Gliomas in NMDAR knockout background (GRIN i∆EC mice) displayed significantly reduced tumor vessels compared to controls ( Fig. 5 g, h) . Altogether, these data show that NMDAR signaling is regulating endothelial sprouting and affect tumor-induced angiogenesis.
xCT inhibition in brain tumors normalizes tumor angiogenesis
Since the expression of xCT correlates with shorter glioma patient survival (7) (NCB molecular brain neoplasia database, data not shown) and the malignancy of gliomas correlates with the degree of angiogenesis, we studied the tumor effects of xCT in vivo. We compared the net tumor volume effects in xCT overexpressing and knockdown gliomas (Suppl . Fig. 4 ). By MRi scans we determined the tumor-induced brain edema and found that xCT KD gliomas showed alleviated brain edema compared to WT gliomas (Suppl. Fig. 4 ). In contrast, xCT OE gliomas displayed increased brain edema and thereby increased spaceoccupying lesions (Suppl. Fig. 4 ).
We further investigated whether therapeutic xCT inhibition could contribute to tumor vessel normalization (vessel parameters equal to controls) in vivo. For this, we implanted syngeneic gliomas orthotopically into brains of animals and monitored vessel architecture by synchrotron X-ray tomographic microscopy (20) (21). Wild-type gliomas displayed pathological vascular alterations in the peritumor and tumor zones in comparison to the contralateral hemisphere without tumor affection serving as a control (Fig. 6) . In particular, Fan et al.,
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vessel branches and lengths of metarterioles and capillaries were significantly altered within the tumor bulk as well as in peritumor regions ( Fig. 6 a-c) . In contrast, siRNA-mediated knock down of xCT in gliomas normalized the vascular pattern (vessel branches and length) resembling those of controls ( Fig. 6 c-e, purple underlined area). Metarterioles and capillaries resembled a phenotype closely to that found in non-affected control brain regions (purple boxed area) ( Fig. 6 c-e ). These findings demonstrate that blocking glutamate secretion abrogates glutamate-triggered tumor vessel growth.
DISCUSSION
The expression level of the glutamate-cysteine antiporter xCT has an important role in determining the malignancy in different human tumors entities (7) (6) (22) (12, 14) . Here, we investigated the underlying mechanisms of xCT in malignant gliomas. We provide evidence for a functional role of the glutamate and NMDAR signaling pathway in tumor vessel formation.
Since tumor-derived glutamate release is one major factor contributing to tumor-associated neurodegeneration, xCT modelling represents an excellent prerequisite to study the causal relation between neurotoxic events and vascular responses. Fostered xCT expression increased peritumoral vascularization and the development of irregular vessel structures.
Similar effects were found by applying the neurotransmitter glutamate into the brain microenvironment. Thus, our data indicate that the effects of xCT on vessels are mediated through discharged glutamate and potential glutamate receptor-dependent signaling in endothelial cells. In fact, the biological effects of glutamate were shown to be in accordance with clinical measurements of peritumoral glutamate in glioma patients, which reached excess levels of up to 100 µM in human patients (10) . Importantly, the increase in excitatory neurotransmitter glutamate levels is toxic for neurons (23) (9), whereas endothelial cells are resistant to high glutamate concentrations and endothelial viability remained unaffected (15) .
In addition, our data and previous reports show that the difference between endothelium and neurons is not due to lack of glutamate signaling in brain vessels (24). Independent lines of evidence already demonstrated that endothelial cells express functional NMDARs and showed that glutamate is involved in regulating arteriole diameter, vasodilation and blood brain barrier disruption (15) (25) (16, 26) . Our data indicate that xCT-dependent effects are mediated by NMDAR signaling and are reversible by the action of NMDAR antagonists.
These findings are further supported by inducible loss-of-function genetics in endothelial cells in vivo. We generated an inducible endothelial cell-specific NR1 knockout model due to the circumstances that conventional NR1 gene disruption causes neonatal lethality (27, 28).
Endothelial cell-specific NR1 knockout revealed that glutamate receptor signaling contributes In conclusion, our data demonstrate that the glutamate transporter xCT and the gliomaderived neurotransmitter glutamate have a crucial role in tumor angiogenesis. Thereby, glutamate receptors of the NMDA subclass operate in endothelial cells and convert the neurotransmitter glutamate to a promoter of angiogenesis. Hence, these data give unique insights into the molecular basis of xCT-mediated tumor angiogenesis and provide fundamental understanding for the biology of glutamate in vascular signaling.
MATERIALS AND METHODS
Chemical, drugs and cell lines
Rodent glioma cell lines F98, C6, and the human glioma cell line U251 were obtained from ATCC/LGC-2397 (Germany) and were cultured under standard condition containing DMEM medium (Biochrom, Berlin, Germany) supplemented with 10% fetale bovine serum (FBS) (Biochrom, Berlin, Germany), 1% Penicillin/Streptomycin (Biochrom, Germany) and 1%
Glutamax (Gibco/Invitrogen, California, USA). Cells were passaged at approx. 80%
confluence by adding trypsin after 1 PBS wash step and incubated for 5 min, then centrifuged at 900 rpm/5 min. Cell lines were transfected as described previously (Savaskan et al., 2008) and maintained under standard conditions. GYKI 47261 dihydrochloride (4-(8-
and MK801(Dizocilpine) were purchased from Tocris Biosciences (R&D Systems GmbH, Wiesbaden, Germany).
RNA isolation and quantitative RT-PCR analysis
Cells were collected when grown at subconfluency, followed by suspension in phosphate buffered saline (PBS). Total RNA was extracted using High Pure RNA Isolation Kit (Roche, Mannheim, Germany) following the manufactory's manual. RNA concentration was determined by NanoVue™ Plus Spectrophotometer (GE Healthcare, UK 
Protein isolation and immunoblotting
For protein analysis cells were seeded in 6-well plates. Cells were maintained under standard conditions for 3 days afterwards medium was removed and cells washed with PBS for one time. Then, 1 ml supplements-free ECGM medium was added and cells incubated in for 1h before further processed. Antibodies were incubated overnight at 4°C in roller tubes, followed by secondary antibodies incubated at room temperature for 1 hour. Detection was performed with ECL plus kit (GE-healthcare, Solingen, Germany).
Expression vectors and knockdown vector cloning
Reverse transcription-polymerase chain reaction was used for full length cloning of xCT from rat, mouse and human mRNA samples (9) . For sequence alignments and homology searches of xCT we utilized the www.ncbi.nlm.nih.gov database and A Plasmid editor software (ApE; MW Davis, Utah, USA). All orthologous sequences of xCT (human, mouse and rat) are deposited at the NCBI database (Human xCT GenBank accession no.
AF252872; Rattus norvegicus xCT GenBank accession no. NM001107673; Mus musculus xCT GenBank Accession no. AB022345). For construct cloning we cloned fragments by PCR and inserted the resulting amplicons into the pEGFP (Takara, Heidelberg, Germany) vector.
According to the critera of Ui-Tei et al. (34) three 19-mer short interfering RNAs were chosen for RNA interference with rat xCT transcripts (GenBank acc. NM001107673). Cloning of the synthetic oligonucleotids into the pSuperGFP vector (pS-GFP; OligoEngine) was performed by digesting the empty vector with EcoR1 and Xho1 according to the manufacturer's instruction. Cells were transfected at low density (<20.000 cells/cm²) and expression analysis was performed as described (6) .
Mutant mice and inducible genetic deletion experiments
For endothelial-cell specific genetic loss-of-function experiments, we inbred loxP-flanked Grin1 (Grin1 lox/lox ) mice (35) with transgenic mice expressing the tamoxifen-inducible recombinase CreERT2 under the control of the endothelial Cdh5 promoter (Cdh5 (PAC)-CreERT2) (36). Cre activation was induced by tamoxifen injection as previously described (37). Briefly, for adult mice, intraperitoneal injection of 100 µl of a 20mg/ml tamoxifen solution was applied daily for a duration of 4 days. For new born mice, 50 µl tamoxifen (1mg/ml) was injected into mice stomach once daily from postnatal 1 to postnatal 4.
Endothelial cell isolation
For isolating endothelial cells from rodents and mice, brain tissue and thoracic aorta were Endothelial sprouting length was measured in an automatized fashion using NIH-Image J software.
Retinal explant cultures
For retinal cultures, we followed the protocol according to Sawamiphak et al. 
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Brain slice cultures were conducted with five days old Wistar rats. Brains were prepared and maintained as previously described (40). Briefly, animals were sacrificed by quick head dissection and brains were removed and kept under ice-cold conditions. Frontal lobes and Cerebellum were dissected of the hemispheres. The remaining brain was cut into 350 µm thick horizontal slices using a vibratome (Leica VT 1000S, Bensheim, Germany). The brain slices were thereafter transferred onto culture plate insert membrane dishes with a pore size of 0.4 µm (GreinerBioOne, Frickenhausen, Germany) and subsequently transferred into sixwell culture dishes (GreinerBioOne) containing 1.2 ml culture medium (MEM-HBSS, 2:1, 25% normal horse serum, 2% L-glutamine, 2.64 mg/ml glucose, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 10 µg/ml insulin-transferrin-sodium selenite supplement and 0.8 µg/ml vitamin C). Slices were cultured in humidified atmosphere (35°C, 5% CO 2 ). After 24 hours, slices were gently washed with 1.2 ml PBS and a full culture medium exchange was performed. At the second day after preparation, 0.1 µl of the cell-medium-suspension (containing 10,000 cells) was placed onto the temporal cortex of the slice by using a 1-µl-Hamilton-syringe. The medium was exchanged every second day. For MK801 treatment, 1.2 µl 1 mg/ml MK801 was applied to the medium reaching final concentration of 100 µM MK801. Slices were fixed and stained for laminin (Sigma) (1:250) for vessel analysis.
Organotypic vascular sponge assay
Agarose cubes were made from 1% agarose containing only PBS (control), 100 µM glutamate or 200 µM glutamate. Cooled agarose hydrogels were then cut into approximately 1mm cubes and implanted on the cortex area of rat brain slices as described. Cubeimplanted brain slices were cultured on semipermeable membrane dishes with a pore size of 0.4 µm (GreinerBioOne, Frickenhausen, Germany) and subsequently transferred into six-well culture dishes (GreinerBioOne) containing 1.2 ml culture medium. The slices were cultured in humidified atmosphere (35°C, 5% CO 2 ). Media change was performed every other day. Four days after sponge cube implantation, slices were fixed and stained with anti-Lamininantibody (Sigma) (1:250) for vessel analysis.
Intravital cerebral tumor-vessel microscopy
Animal experiments were performed according to local animal welfare guidelines. Adult athymic nude mice (Jax: 002019) were anesthetized deeply. Anesthesia was verified by foot paw pinching reflex control. Mouse cranial window by craniotomy was described previously (41). Briefly, the mice were stereotactically fixated and a 6 mm Ø craniotomy was performed using a micro-drill (0.5 mm, Figure 3c ). The Dura matter was carefully removed using micro forceps, the tumor spheroid was carefully placed on a vessel free area of the cortex. The window was sealed with a 7 mm Ø cover glass and the skin was sutured. Intravital epifluorescence video microscopy was performed 7, 10, and 14 days following implantation 
In vivo tumor cell implantation
Fischer 344 rat were stereo-tactically injected with F98 rat glioma cells stably expressing scrambled shRNA or pEGFP vector (control), pEGFP-xCT and xCT specific shRNA (xCT KD ) constructs as described previously (6) .
Frozen sections and immunofluorescence
Rat brains were isolated 11 days after tumor implantation and fixed in 4% PFA overnight at 4 °C. Thereafter, fixed brains were washed with PBS and incubated in 20% sucrose for 3 days. 
Scanning electron microscopy
Brain vessel corrosion casts from tumor-implanted rats were mounted on aluminum stabs and sputtered with 10 nm gold. The vasculature of the specimens was scanned with a Hitachi S4000 scanning electron microscope and subsequently analyzed with Image J (Heinzer et al., 2008).
Synchrotron microscopic CT and vessel analysis
Eighteen days post implantation, rats were deeply anesthetized, killed and perfused with the PU4ii polymer resin (Vasqutec, Zurich, Switzerland) as described previously (42). Resulting vascular reconstructions of regions of interest (ROIs) of the contralateral hemisphere (control) peritumor and tumor cubes (740.16µm 3 per ROI) were reconstructed using Amira Software (Visage Imaging, Andover USA). The cubes were cut into cylinders to prevent artifacts. Contrast dependent object identification was used to identify the blood vessels.
Resulting data spreadsheets and self-designed programs and macros were processed using Microsoft Excel 2007. Vessels were categorized by diameter according to the anatomical classification of blood vessels: Arterioles (21 -50 µm), metarterioles (11 -20 µm) and capillaries (3 -10 µm). 
Calcium imaging
Statistical analysis
Data from experiments were obtained from at least three independent experiments if not otherwise stated. Statistical analysis was performed using the ANOVA test using Graphpad Prism (GraphPad Inc., CA, USA) if not otherwise described in the figure legends. The level of significance was set at P * < 0.05, P * * < 0.01, P * * * <0.001 according to the international conventions. Error bars represent ± S.D. calculated (means ± s.d., *P < 0.05, from n ≥ 4). All significance analyses were conducted using student's t. test. 
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